Targets, biomarkers, AI discovery, and Phases I–III clinical results.
An article joins this feed when it matches these terms. Each one is also a search of its own.
On September 24, 2026, LC-Bio Technologies (Hangzhou) Co., Ltd. (“LC-Bio”), 10x Genomics, and Vitaura (Beijing) Technology Co., Ltd. (“Vitaura”) held a signing ceremony in Hangzhou to formalize a three-party strategic cooperation agreement. The three companies intend to jointly build a “data–mod LC-Bio…
A new Cambridge, UK-based biotech says it wants to become a world leader in developing drugs based on microbiome biology. The microbiome is made up of trillions of bacteria that live in the human gut and elsewhere in the body,…
DeAngelis spoke with Isomorphic executives and former employees for this story, along with outside experts. On a day in late 2024, Avery Klemmer found herself on yet another transatlantic flight with her colleagues at the VC firm Thrive Capital. The team…
AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented data, weak metadata, slow pipelines, and poor data locality can…
While the spotlight often shines brightest on AI’s impact in medicine, its transformative power extends far beyond drug discovery. AI scientific discovery is rapidly reshaping fields like materials science and climate research, opening up entirely new avenues for innovation that…
Every experiment involving cellular research compounds depends on one thing above all else: knowing whether the effect you’re seeing actually came from your compound, or from something else entirely. That’s the entire purpose of an experimental control, and it’s a…
Artificial intelligence is not a magic solution to every pharmaceutical challenge. However, when combined with scientific expertise, reliable data, and rigorous testing, it can help researchers and pharmaceutical companies make better-informed decisions. From AI-powered drug discovery to personalized medicine, here…
For every new binding arm added to a molecule construct, the number of potential combinations expands, making molecule selection an increasingly complex exercise. As multispecific formats proliferate, service providers are increasingly working with sponsors to determine which molecule to build…
Market.us offers its clients a one-stop solution platform for all market research needs. Our expert panel includes specialists in industries and sectors such as Chemicals, Healthcare, Medical, ICT and other related fields, apart from professional survey teams and competent…
Home ➤ Press Releases ➤ AI in Bioinformatics Market Poised to Grow at 42.9% CAGR from 2024 to 2033 The Global AI In Bioinformatics Market size is expected to be worth around USD 136.3 Million by 2033, from USD 3.8 Million in 2023, growing at a CAGR of 42.9% during…